20^th Global Congress on Biotechnology March 5-7, 2018 Park Inn by Radisson Hotel London, UK

David Rabuka received a PhD in chemistry at the UC Berkeley as a Chevron Fellow in the lab of Carolyn Bertozzi. His research included developing and applying the SMARTagTM platform technology to cell surface modification. Prior to joining Bertozzi’s lab, David worked at the Burnham Institute synthesizing complex glycans followed by Optimer Pharmaceuticals, which he joined as an early employee, focused on the development of glycan and macrolide based antibiotics. He was CSO, President and co-founder of Redwood Bioscience where he developed novel protein conjugation methods and biotherapeutic applications such as antibody-drug conjugates. Redwood Bioscience was acquired by Catalent Pharma Solutions in Oct 2014, where David has continued to apply the SMARTagTM technology with various collaborators and partners as a Global Head of R&D. David graduated with a double honors BS in chemistry and biochemistry from the University of Saskatchewan, where he received the Dean’s Science Award, and holds an MS in chemistry from the University of Alberta. He is an author on over 45 major publications, as well as numerous book chapters and an inventor in over 30 patents.

His research interest is towards novel protein conjugation methods and biotherapeutic applications such as antibody-drug conjugates.

Thomas McKeon has received his PhD in Biochemistry at UC Berkeley with Postdoctoral Research in Plant Biochemistry at UC Davis. He has over 100 publications, mostly in Plant Lipid Enzymology and Molecular Biology. He is an Editor and author for the book chapter “Industrial Oil Crops”. He is an Editor for Biocatalysis and Agricultural Biotechnology (BAB), a Board Member for American Oil Chemists Society (AOCS) Biotechnology Division and International Society for Biocatalysis and Agricultural Biotechnology (ISBAB). He has organized conferences for ISBAB and for US-Japan Natural Resources (UJNR) Food and Agriculture Panel.

Biocatalysis, Plant Biochemistry , Agricultural Biotechnology , Industrial Oil Crops

Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980.Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences,National Center for Immunology (Russia), NIH, Bethesda, USA) and British Society for Immunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Faculty Professor of I.M. Sechenov First Moscow State Medical University and Of A.I.Evdokimov Moscow State Medical & Dental University. From 2007, Suchkov is the First Vice-President and Dean of the School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the International Journal“Biomedical Science” (Russian Academy of Sciences and Royal Society of Chemistry, UK) and The International Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Diseases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Personalized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology and others. Dr Suchkov is known as an author of the Concept of post-infectious clinical and immunological syndrome, co-author of a concept of abzymes and their impact into the pathogenesis of autuimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branch of health services.

Predictive, Preventive and Personalized Medicine,Immunology, Medicine, Pathology

Fuad Fares has completed his D.Sc studies at the Faculty of Medicine, Technion-Israel Institute of Technology, and postdoctoral studiesat the Department of Molecular Biology and Pharmacology, School of Medicine, Washington University, St. Louis Missouri. He is the director of the Department of Molecular Genetics at Carmel Medical Center and associated professor at the Department of Human Biology, University of Haifa. He has published more than 75 papers in reputed journals and serving as a member of the Israel Council for Higher Education. He is the inventor of designing long-acting recombinant proteins and the initiator of PROLOR Biotech company

Molecular Endocrinology Molecular Genetics Apoptosis cancer

lan Chet has completed his PhD in Microbiology at the Faculty of Agriculture of the Hebrew University of Jerusalem in Rehovot. He has published 390 articles, edited five books and holds 38 patents. He has served as a Dean of the Faculty of Agriculture and Vice President of the Hebrew University. Later, he was the President of the Weizmann Institute of Science and nominated “Institute Professor”. He was also a Visiting Professor at Harvard, Colorado State, Cornell, Rutgers and Lund Gottingen Universities. He was awarded with many prizes, among them, the Max-Planck, the Israel prize and the Wolf Prize. He has also received the Officer’s Cross of the Order of Merit of Germany and the Legion of Honor of France. Furthermore, he was recognized with an Honorary Doctorate from Lund, Haifa and Naples Universities. He is a Member of the Israel Academy of Sciences and Humanities, the European Academy of Sciences and Academia Europea. He held the previous position of Deputy Secretary General at the Secretariat of the Union for the Mediterranean.

His research concerns with the biological control of plant disease using environment-friendly microorganisms, focusing on the basic, applied, and biotechnological aspects of this field.

Dr Fernando de la Calle is currently the Head of the Microbiology Dpt. within Drug Discovery (R&D) at PharmaMar, biopharma involved in the development and commercialization of anticancer drugs of marine origin. He received his Ph.D. in Molecular Biology from UAM (Madrid) in 1998. He also completed an Executive-MBA at IDE-CESEM (Madrid) in 2005. He has more than 25 years’ experience working in drug discovery from marine microorganisms. He is an Expert in Applied Biotechnology, Molecular characterization of Bacterial Biodiversity and the use of Biotechnology tools for Drug Discovery . Co-author of the current hemisynthetic process for manufacturing the anticancer Yondelis®, the first European marine derived compound approved. In addition, he has been external advisor for biotechnology issues to the Spanish Government (INCUAL), current member of the International Advisory Group of european ERA-NET for Marine Biotechnology and Biodiversity, reviewer for H2020 and ERA-NET projects and the scientific contact person from PharmaMar for FP7/H2020 EU projects related to Marine Biodiversity such as MAMBA, MaCuMBA, MicroB3 and INMARE as WP leader. Principal Investigator in more than 10 other nationally funded projects.

Biotechnology, Molecular characterization of Bacterial Biodiversity and the use of Biotechnology tools for Drug Discovery

Liliana Rubio Chemical Engineer, Master in Project Management, MBA in Business Administration, MBA in Innovation Management, Specialist in polymer; over 18 years’ experience working on new business, R&D and marketing. Lecturer on innovation & sustainability at universities and the main trade fairs of polymer & Fashion Industry in Latin America, EUA and Asia. Author of several articles that have been publish in technology and business magazines.Founder of PMO Polymer Business Intelligence is a Project Management Office, located in Sao Paulo-Brazil, dedicated to project management consulting, mentoring, covering project planning, implementation and execution through a front-to-end creative quantification approach. Founder of SmartTex Hub ecosystem for the value chain of textile Industry and final applications.

Bio Composites,Nano Biotechnology